Caplacizumab Therapy in Immune Thrombotic Thrombocytopenic Purpura

被引：0
作者：
Reti, Marienn [1 ]
Sinkovits, Gyorgy [2 ]
Varkonyi, Andrea [1 ]
Kiraly, Agnes [1 ]
Farkas, Zita [1 ]
Bogsch, Luca [1 ]
Icleanu, Andreea-Adela [2 ]
Masszi, Tamas [2 ]
Valyi-Nagy, Istvan [1 ]
Prohaszka, Zoltan [2 ]
Remenyi, Peter Pal [1 ]
机构：
[1] Cent Hosp Southern Pest, Natl Inst Hematol & Infect Dis, Dept Hematol & Stem Cell Transplantat, Budapest, Hungary
[2] Semmelweis Univ, Eotvos Lorand Res Network, Off Supported Res Grp, Dept Internal Med & Hematol, Budapest, Hungary
来源：
BLOOD | 2023年 / 142卷
关键词：
D O I：
10.1182/blood-2023-186633
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Caplacizumab: a change in the paradigm of thrombotic thrombocytopenic purpura treatment
    le Besnerais, Maelle
    Veyradier, Agnes
    Benhamou, Ygal
    Coppo, Paul
    [J]. EXPERT OPINION ON BIOLOGICAL THERAPY, 2019, 19 (11) : 1127 - 1134
  • [32] Cost effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura
    Goshua, George
    Sinha, Pranay
    Hendrickson, Jeanne E.
    Tormey, Christopher
    Bendapudi, Pavan K.
    Lee, Alfred Ian
    [J]. BLOOD, 2021, 137 (07) : 969 - 976
  • [33] USE OF CAPLACIZUMAB IN PEDIATRIC THROMBOTIC THROMBOCYTOPENIC PURPURA PATIENTS
    Graciaa, Sara
    Sidonio, Robert
    Zerra, Patricia
    Rollins, Margo
    Briones, Michael
    Chonat, Satheesh
    [J]. PEDIATRIC BLOOD & CANCER, 2023, 70 : S139 - S139
  • [34] Caplacizumab treatment for acquired refractory thrombotic thrombocytopenic purpura
    Khan, Sundas
    Landry, Kara
    Umyarova, Elvira
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 191 (02) : E44 - E46
  • [35] Delayed Thrombotic Complications in a Thrombotic Thrombocytopenic Purpura Patient Treated With Caplacizumab
    Cilla, Nicolas
    Dallemagne, Julie
    Vanhove, Marie
    Stordeur, Patrick
    Motte, Serge
    De Wilde, Virginie
    [J]. JOURNAL OF HEMATOLOGY, 2020, 9 (03) : 84 - 88
  • [36] Alternate-day dosing of caplacizumab for immune-mediated thrombotic thrombocytopenic purpura
    Kuehne, Lucas
    Kaufeld, Jessica
    Voelker, Linus A.
    Wendt, Ralph
    Schoenermarck, Ulf
    Haegele, Holger
    Osterholt, Thomas
    Eichenauer, Dennis A.
    Bieringer, Markus
    Bergwelt-Baildon, Anke
    Fischereder, Michael
    Buxhofer-Ausch, Veronika
    Menne, Jan
    Brinkkoetter, Paul T.
    Knoebl, Paul
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2022, 20 (04) : 951 - 960
  • [37] Should all patients with immune-mediated thrombotic thrombocytopenic purpura receive caplacizumab?
    Picod, Adrien
    Veyradier, Agnes
    Coppo, Paul
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2021, 19 (01) : 58 - 67
  • [38] Alternate-Day Dosing of Caplacizumab for Immune-Mediated Thrombotic Thrombocytopenic Purpura
    Kuehne, Lucas
    Eichenauer, Dennis A.
    Knoebl, Paul
    Voelker, Linus A.
    Kaufeld, Jessica
    Wendt, Ralph
    Haegele, Holger
    Osterholt, Thomas
    Bieringer, Marcus
    Buxhofer-Ausch, Veronika
    Menne, Jan
    Schoenermarck, Ulf
    Brinkkoetter, Paul
    [J]. BLOOD, 2021, 138
  • [39] Cost-Effectiveness of Caplacizumab in the Warranty Program in Immune Thrombotic Thrombocytopenic Purpura in the USA
    Sullivan, Sean D.
    Chaturvedi, Shruti
    Gautam, Preety
    Arnaud, Alix
    [J]. BLOOD, 2023, 142
  • [40] Caplacizumab as an emerging treatment option for acquired thrombotic thrombocytopenic purpura
    Elverdi, Tugrul
    Eskazan, Ahmet Emre
    [J]. DRUG DESIGN DEVELOPMENT AND THERAPY, 2019, 13 : 1251 - 1258
12345